Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study

Tian, Zhichao; Wang, Jiaqiang; Yang, Jiong; Zhang, Peng; Wang, Xin; Zhang, Fan; Li, Po; Yao, Weitao

doi:10.1007/s10637-021-01139-w

Cited by 2 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the efficacy and safety of nab-paclitaxel combined with a PD-1 inhibitor for patients with STS have not been reported. We have extensive experience in the treatment of patients with advanced STS using nab-paclitaxel or PD-1 inhibitors [26,27]. Some patients were treated with nab-paclitaxel plus a PD-1 inhibitor.…”

Section: Introductionmentioning

confidence: 99%

Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background There is increasing evidence that combination therapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and programmed cell death protein 1 (PD-1) inhibitor is safe and efficacious in treating many types of malignant tumors. However, clinical data demonstrating the effect of this treatment combination for patients with metastatic soft tissue sarcoma (STS) are currently limited. Methods The clinical data of patients with metastatic STS who received nab-paclitaxel plus PD-1 inhibitor (sintilimab) therapy between January 2019 and February 2021 were retrospectively analyzed. The effectiveness and safety of the combined treatment were evaluated in terms of the median progression-free survival (PFS), estimated using the Kaplan–Meier method. The univariate Cox proportional hazards model was used to analyze the relationship between clinicopathological parameters and PFS. All statistical analyses were two-sided; P < 0.05 was considered statistically significant. Results A total of 28 patients treated with nab-paclitaxel plus sintilimab were enrolled in this study. The objective response rate was 25%, the disease control rate was 50%, and the median PFS was 2.25 months (95% CI = 1.8–3.0 months). The most common grade 1 or 2 adverse events (AEs) were alopecia (89.3%; 25/28), leukopenia (25.0%; 7/28), fatigue (21.4%; 6/28), anemia (21.4%; 6/28), and nausea (21.4%; 6/28). The most common grade 3 AEs were neutropenia (10.7%; 3/28) and peripheral neuropathy (10.7%; 3/28). No grade 4 AEs were observed. Among the present study cohort, patients with angiosarcoma (n = 5) had significantly longer PFS (P = 0.012) than patients with other pathological subtypes, including undifferentiated pleomorphic sarcoma (n = 7), epithelioid sarcoma (n = 5), fibrosarcoma (n = 4), synovial sarcoma (n = 3), leiomyosarcoma (n = 2), pleomorphic liposarcoma (n = 1), and rhabdomyosarcoma (n = 1); those who experienced three or more AEs had significantly longer median PFS than those who experienced less than three AEs (P = 0.018). Conclusion Nab-paclitaxel plus PD-1 inhibitor is a promising treatment regimen for advanced STS. Randomized controlled clinical trials are required to further demonstrate its efficacy and optimal application scenario.

show abstract

Section: Introductionmentioning

confidence: 99%

Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…É necessário durante o tratamento estabelecer uma terapia adjuvante eficaz para sarcomas de tecidos moles (STSs), estudos demonstram que a administrado em combinação com quimioterapia à base de doxorrubicina, melhora a eficácia do tratamento (Tian;et al, 2021;Greto;et al,2018).…”

Section: Introductionunclassified

Diagnóstico de miofibrossarcoma de alto grau em cão – relato de caso

Kavasaki

Barboza

Stein

et al. 2021

RSD

View full text Add to dashboard Cite

Os Sarcomas de tecidos moles (STM) na oncologia veterinária, compreendem um grupo de neoplasias mesenquimais malignas, com acometimento principalmente da pele e subcutâneo, possuem margens mal definidas com altos índices de recidiva local e moderado potencial metastático. O diagnóstico de rotina é realizado com base no histórico do animal, sinais clínicos, porém a confirmação é realizada através de exames citológicos e histopatológicos. Complementarmente a quimioterapia, radioterapia e remoção cirúrgica são utilizados para proporcionar uma maior sobrevida aos pacientes. O presente estudo tem por objetivo reportar um caso de Mixofibrossarcoma de Alto Grau, detectado através do exame imuno-histoquimico, uma variação do (STM), em um paciente canino, fila brasileiro, macho, com um ano de idade, atendido em uma clínica veterinária situada no município de Vilhena- Rondônia, apresentando inicialmente um nódulo em região da escápula direita, com evolução rápida e crescimento progressivo após remoção cirúrgica. Os tutores optaram pela eutanásia do animal.

show abstract

Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study

Cited by 2 publications

References 27 publications

Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study

Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study

Diagnóstico de miofibrossarcoma de alto grau em cão – relato de caso

Contact Info

Product

Resources

About